Brief: Hansoh Pharmaceutical Says Drug Registration Approval Of Fourth Indication Of Aumolertinib Mesilate Tablets Granted By NMPA
09/05/2025 11:44
May 9 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: DRUG REGISTRATION APPROVAL OF FOURTH INDICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) GRANTED BY NMPA Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion